Amylyx Pharmaceuticals AMLX
$26.02 −$0.18 (-0.69%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $25.55 -1.81%
Open$25.64
Prev close$26.20
Day range$25.52 – $26.40
Volume1.14M
Market cap$3.35B
P/E (TTM)–
Dividend yield–
AMLX Stock News
Headlines matching Amylyx Pharmaceuticals or the AMLX ticker, most recent first.
- Baird Initiates Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $28
- A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $24 to $34
- Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $26
- Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $26 Positive
- Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57 Positive
- LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44
- H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $55
- Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $42
- TD Cowen Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating
- Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $55 Positive
- A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $32 to $55
- Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $30 Positive
- LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $24
- Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Heart Test Laboratories, Inc. (HSCS) and Align Tech (ALGN)
- Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $24 Positive
No comments yet — be the first to weigh in on AMLX.
Sign in to join the discussion.